Thoughts on people, teams, organizations, communities, effectiveness and success
Quitting a promising job is tough, and it’s made even tougher in a choppy economy. The fact of the matter though is that sometimes the greater risk to you is to stay at a job rather than quit and hope you find something else.
Though the stink of Enron has mostly faded, former employees of one of the biggest corporate scandals still feel the effects from having that firm’s name on their resume.… Read the rest
I got a chance to catch up with my friend CB yesterday. Bright, hardworking, smart as a whip, and results driven, she’s one of about five people in my life who I would both hire AND work for. Like a lot of others in the bumpy economy, she was in the wrong place at the wrong time recently – is between roles – and is now looking for her next opportunity.… Read the rest
No.
As reported by the San Francisco Business Times , Art will leave May 1, followed by Sue Desmond-Hellmann and other senior execs later this year. No specific dates were noted for Sue Desmond-Hellman and the others leaving the company. [Update 5/1/2009 : Yesterday was Sue’s last day at Genentech. The SF Business Times reported that she has been recommended by a search committee to be the new chancellor of the University of California San Francisco.… Read the rest
Neither Roche Chairman Franz Humer nor CEO Severin Schwan have called me up to ask how I’d handle the talent side of their Genentech acquisition. Perhaps they will, but they’ve also been pretty mum on their plans moving forward for the talent at 1 DNA Way .
As someone who has made their livelihood in the talent assessment business as a coach to managers and teams for over 25 years – and to save Franz and Severin a long distance phone call charge – here are some things I’d be thinking about if I were on point with the talent side of the Genentech project.… Read the rest
Business and organizational observers in San Francisco and its environs will get a first hand view of how smart – or not-so-smart – the buyers of Genentech and Barclays Global Investor’s iShares unit are in getting real value for their acquisitions. [Update: See Kathleen Pender’s good overview column Net Worth from the April 12th San Francisco Chronicle here ]
While the buyers are different, the name of the game is the same: get value equal or greater to your purchase price.… Read the rest
In Roman Catholic theology, limbo is that afterlife condition for those who die without being assigned to hell. For employees in companies waiting for the post-acquisition dust to settle such as Genentech, or for those waiting for part of the organization to be halved off, such as Barclays Global Investors (BGI) with its iShares division, limbo is a pretty good description of what it’s like to be inside the organization.… Read the rest